CN114206930A - 针对抗cd73抗体和变体的方法和组合物 - Google Patents

针对抗cd73抗体和变体的方法和组合物 Download PDF

Info

Publication number
CN114206930A
CN114206930A CN202080053981.XA CN202080053981A CN114206930A CN 114206930 A CN114206930 A CN 114206930A CN 202080053981 A CN202080053981 A CN 202080053981A CN 114206930 A CN114206930 A CN 114206930A
Authority
CN
China
Prior art keywords
seq
acid sequence
amino acid
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080053981.XA
Other languages
English (en)
Inventor
姜伟东
陈奕颖
曾琪铃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fuhong Hanlin Biomedical Co ltd
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Fuhong Hanlin Biomedical Co ltd
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fuhong Hanlin Biomedical Co ltd, Shanghai Fuhong Hanlin Biopharmacy Co ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Fuhong Hanlin Biomedical Co ltd
Publication of CN114206930A publication Critical patent/CN114206930A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供了抗CD73抗体、变体、和其抗原结合片段，这些抗体、变体、和其抗原结合片段以高亲和力与人CD73结合并抑制CD73的酶活性，并且任选地诱导CD73内化。还提供了编码该抗CD73抗体、变体、和其抗原结合片段的分离的核酸分子，和相关的表达载体，和宿主细胞。提供了制备抗CD73抗体、变体、和其抗原结合片段的方法。还提供了相关的药物组合物和使用这些药物组合物治疗受试者的方法。

Description

PCT国内申请，说明书已公开。

Claims (54)

  1. PCT国内申请，权利要求书已公开。
CN202080053981.XA 2019-07-26 2020-07-17 针对抗cd73抗体和变体的方法和组合物 Pending CN114206930A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019106832875 2019-07-26
CN201910683287.5A CN112300279A (zh) 2019-07-26 2019-07-26 针对抗cd73抗体和变体的方法和组合物
PCT/CN2020/102678 WO2021017892A1 (zh) 2019-07-26 2020-07-17 针对抗cd73抗体和变体的方法和组合物

Publications (1)

Publication Number Publication Date
CN114206930A true CN114206930A (zh) 2022-03-18

Family

ID=74230130

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910683287.5A Withdrawn CN112300279A (zh) 2019-07-26 2019-07-26 针对抗cd73抗体和变体的方法和组合物
CN202080053981.XA Pending CN114206930A (zh) 2019-07-26 2020-07-17 针对抗cd73抗体和变体的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910683287.5A Withdrawn CN112300279A (zh) 2019-07-26 2019-07-26 针对抗cd73抗体和变体的方法和组合物

Country Status (7)

Country Link
US (1) US20220162334A1 (zh)
EP (1) EP4006054A4 (zh)
JP (1) JP2022542165A (zh)
CN (2) CN112300279A (zh)
BR (1) BR112022001359A2 (zh)
CA (1) CA3145897A1 (zh)
WO (1) WO2021017892A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294436A (en) 2020-01-03 2022-09-01 Incyte Corp Anti-cd73 antibodies and their uses
US20240174763A1 (en) * 2021-02-24 2024-05-30 Novoprotein Scientific Inc. Anti-human cd73 antibody and use thereof
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
CN117337306A (zh) * 2021-05-28 2024-01-02 和铂医药(上海)有限责任公司 靶向pd-l1和cd73的特异性结合蛋白
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274835A1 (en) * 2012-10-04 2015-10-01 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US20170143825A1 (en) * 2014-07-16 2017-05-25 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
CN107001474A (zh) * 2014-11-21 2017-08-01 百时美施贵宝公司 抗cd73抗体及其用途
US20180237536A1 (en) * 2014-10-10 2018-08-23 Innate Pharma Cd73 blockade
CN109476740A (zh) * 2016-03-04 2019-03-15 百时美施贵宝公司 利用抗cd73抗体的联合治疗
CN109923126A (zh) * 2016-09-16 2019-06-21 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
US20190225691A1 (en) * 2016-10-30 2019-07-25 Shanghai Henlius Biotech Inc. Anti-pd-l1 antibodies and variants

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
PT90959B (pt) 1988-06-24 1995-05-04 Dow Chemical Co Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
EP0353450B1 (en) 1988-06-24 1995-03-29 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5808110A (en) 1994-07-21 1998-09-15 Akzo Nobel Nv Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
IL122910A (en) 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2288705C (en) 1997-05-06 2008-03-18 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2001522802A (ja) 1997-11-06 2001-11-20 アメリカン・サイアナミド・カンパニー 大腸ポリープを治療するためのチロシンキナーゼインヒビターとしてのキナゾリン誘導体の使用
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
ES2877080T3 (es) * 2014-11-10 2021-11-16 Medimmune Ltd Moléculas de unión específicas para cd73 y usos de las mismas
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
WO2018110555A1 (ja) * 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
CN112279918A (zh) * 2017-01-24 2021-01-29 天境生物科技(上海)有限公司 Cd73抗体及其用途
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CA3066774A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) * 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274835A1 (en) * 2012-10-04 2015-10-01 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US20170143825A1 (en) * 2014-07-16 2017-05-25 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
US20180237536A1 (en) * 2014-10-10 2018-08-23 Innate Pharma Cd73 blockade
CN107001474A (zh) * 2014-11-21 2017-08-01 百时美施贵宝公司 抗cd73抗体及其用途
CN109476740A (zh) * 2016-03-04 2019-03-15 百时美施贵宝公司 利用抗cd73抗体的联合治疗
CN109923126A (zh) * 2016-09-16 2019-06-21 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
US20190218295A1 (en) * 2016-09-16 2019-07-18 Shanghai Henlius Biotech Inc. Anti-pd-1 antibodies
US20190225691A1 (en) * 2016-10-30 2019-07-25 Shanghai Henlius Biotech Inc. Anti-pd-l1 antibodies and variants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENBANK: "Accession No.： MOO75748.1，immunoglobulin heavy chain junction region, partial [Homo sapiens]", 《GENBANK》 *
LUCA ANTONIOL: "38-43", 《ONCOIMMUNOLOGY .》, vol. 5, no. 9, pages 1 - 3 *
张曙光: "靶向CD73在肿瘤联合治疗中的研究进展", 《中国现代医学杂志》, vol. 29, no. 16, pages 38 - 43 *

Also Published As

Publication number Publication date
US20220162334A1 (en) 2022-05-26
JP2022542165A (ja) 2022-09-29
EP4006054A1 (en) 2022-06-01
EP4006054A4 (en) 2023-11-29
BR112022001359A2 (pt) 2022-05-24
CA3145897A1 (en) 2021-02-04
WO2021017892A1 (zh) 2021-02-04
CN112300279A (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
JP7391027B2 (ja) 抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体による治療のための投薬
KR102156199B1 (ko) 항-cd73 항체 및 이것의 사용
JP7003036B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
CN106103486B (zh) 抗ox40抗体和使用方法
CA2678181C (en) Antibodies against erbb3 and uses thereof
WO2021017892A1 (zh) 针对抗cd73抗体和变体的方法和组合物
JP2020180135A (ja) 抗ｐｄ−ｌ１抗体およびその使用
US8933202B2 (en) AXL antibodies
US11028173B2 (en) Anti-PD-1 antibodies
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
KR20180008449A (ko) 암에 대한 치료 및 진단 방법
CN109196121A (zh) 用于癌症的治疗和诊断方法
KR20160146747A (ko) 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
JP2017537090A (ja) Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
US9145462B2 (en) Glioblastoma multiforme-reactive antibodies and methods of use thereof
KR20200115596A (ko) Cd70에 특이적인 항체 및 이의 용도
US20230159631A1 (en) Anti-g-csf antibodies and uses thereof
US20180193456A1 (en) Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies
JP2023525085A (ja) がんを治療するための組成物および方法
US20230192839A1 (en) Antibodies having conditional affinity and methods of use thereof
JP2022548978A (ja) 薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
CN113710706A (zh) 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
WO2021227326A1 (en) Compositions and methods for treating cancer
CN115066613A (zh) 用于治疗血液癌症的诊断和治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40071709

Country of ref document: HK